The new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers

Multiple Sclerosis

Volumn 12, Issue 3, 2006, Pages 325-328

  Petzold, Axel ^a   Eikelenboom, M J ^b   Keir, G ^a   Polman, C H ^b   Uitdehaag, B M J ^b   Thompson, E J ^a   Giovannoni, G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarker; MSSS; Multiple sclerosis

Indexed keywords

BIOLOGICAL MARKER; FERRITIN; GLIAL FIBRILLARY ACIDIC PROTEIN; NEUROFILAMENT PROTEIN; PROTEIN S100B;

ADULT; AGED; ARTICLE; ASTROCYTOSIS; CELL ACTIVATION; CEREBROSPINAL FLUID EXAMINATION; CLINICAL ARTICLE; CORRELATION FUNCTION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GLIA CELL; GLOBAL MULTIPLE SCLEROSIS SEVERITY SCALE; HEAVY CHAIN; HUMAN; INTERMETHOD COMPARISON; MALE; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; PROTEIN PHOSPHORYLATION; RATING SCALE; STATISTICAL ANALYSIS; VALIDATION PROCESS;

ADULT; AXONS; BIOLOGICAL MARKERS; DIAGNOSTIC TECHNIQUES, NEUROLOGICAL; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROFILAMENT PROTEINS; NEUROGLIA; PHOSPHORYLATION; SEVERITY OF ILLNESS INDEX;

EID: 33744830289     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135248505ms1277oa     Document Type: Article

References (13)

1. Roxburgh RHSR, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S et al. Multiple Sclerosis Severity Score. Using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-51.
2. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration & loss. J Neurol Sci 2005; 233: 183-98.
3. Petzold A, Eikelenboom MJ, Gveric D, Keir G, Chapman M, Lazeron RH et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 2002; 125: 1462-73.
4. Rosengren LE, Lycke J, Andersen O. Glial fibrillary acidic protein in CSF of multiple sclerosis patients - relation to neurological deficit. J Neurol Sci 1995; 133: 61-65.
5. Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neuro-filament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003; 61: 1720-25.
6. Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64: 402-404.
7. Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, Giovannoni G. Quantification of neurodegeneration by measurement of brain-specific proteins. J Neuroimmunol 2003; 138: 45-48.
8. G Pryce, Z Ahmed, DJ Hankey, Jackson SJ, Croxford JL, Pocock JM et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003; 127: 2191-202.
9. Jackson SJ, Baker D, Cuzner ML, Diemel LT. Cannabinoid-mediated neuroprotection following interferon-gamma treatment in a three-dimensional mouse brain aggregate cell culture. Eur J Neurosci 2004; 20: 2267-75.
10. Petzold A, Eikelenboom MJ, Keir G, Grant D, Lazeron RH, Polman CH et al. Axonal damage accumulates in the progressive phase of multiple sclerosis: a 3-year follow-up study. J Neurol Neurosurg Psychiatry 2005; 76: 206-11.
11. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
12. Rejdak K, Eikelenboom MJ, Petzold A, Thompson EJ, Stelmasiak Z, Lazeron RH et al. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology 2004; 63: 1439-45.
13. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-11.